Post-Transplant Lymphoproliferative Disorders

Annual Review of Medicine - Tập 56 Số 1 - Trang 29-44 - 2005
Stephen Gottschalk1, Cliona M. Rooney1, Helen E. Heslop1
1Center for Cell and Gene Therapy, Texas Children's Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston, Texas 77030;, ,

Tóm tắt

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.

Từ khóa


Tài liệu tham khảo

Penn I, 1969, Transplant. Proc., 1, 106

10.1097/00007890-199911270-00015

10.1097/00000478-200003000-00006

10.1056/NEJM200008173430707

10.1056/NEJMra032015

10.1146/annurev.immunol.15.1.405

10.1084/jem.187.9.1395

10.1084/jem.191.10.1649

10.1016/S1040-8428(00)00046-9

10.1038/sj.onc.1206556

10.1016/S0140-6736(95)91150-2

10.1182/blood.V92.5.1549

10.1016/S0140-6736(03)12271-4

10.1038/nri1201

10.1182/blood.V92.7.2294

10.1073/pnas.0400945101

Curtis RE, 1999, Blood, 94, 2208

10.1182/blood.V87.9.3633.bloodjournal8793633

10.1046/j.1365-2141.1998.00972.x

10.1182/blood.V91.8.3079.3079_3079_3083

10.1053/bbmt.2001.v7.pm11529490

10.1016/S1083-8791(03)00228-3

10.1097/00007890-199711270-00011

10.1097/00007890-198804000-00011

10.1016/S0022-3476(97)70173-2

10.1097/00000478-199803000-00004

10.1034/j.1399-3046.2002.00021.x

10.1200/JCO.1999.17.12.3835

10.1182/blood.V85.2.552.552

10.1093/ajcp/107.4.419

10.1097/00007890-200104270-00012

10.1182/blood.V97.5.1165

10.1182/blood.V99.12.4364

10.1111/j.1365-2141.1995.tb08904.x

10.1182/blood.V98.4.972

10.1182/blood-2003-12-4287

10.1128/JCM.39.4.1407-1415.2001

10.1086/315828

10.1182/blood-2002-10-3001

10.1097/01.TP.0000093997.83754.2B

10.1038/sj.bmt.1703806

10.1016/S0031-3955(03)00127-5

10.1182/blood.V71.5.1234.1234

10.1056/NEJM199105233242102

10.1023/A:1008372814223

10.1182/blood.V95.4.1502.004k40_1502_1505

10.1046/j.1365-2141.2001.03041.x

10.1097/00007890-200201150-00019

10.1056/NEJM200109273451315

10.1111/j.1600-065X.1997.tb00983.x

10.1056/NEJM199409083311017

10.1182/blood.V91.10.3654

10.1182/blood.V97.1.63

10.1038/nm0596-551

10.1016/j.bbmt.2003.09.017

10.1182/blood.V97.4.835

10.1182/blood.V95.3.807.003k24_807_814

10.1016/S0140-6736(84)90994-2

10.1002/ijc.2910430115

10.1034/j.1399-3062.2001.003002097.x

10.1097/00007890-199709270-00010

Feng WH, 2002, Cancer Res., 62, 1920

10.1097/00001622-200109000-00008

10.1164/ajrccm.153.4.8616579

10.1097/00007890-199812270-00035

10.1182/blood.V97.6.1590

10.1097/00007890-200003150-00027

10.1016/S0889-8588(05)70473-1

10.1023/A:1008263226895

10.1016/S0140-6736(00)02879-8

10.1097/01.TP.0000129813.54517.25

10.1034/j.1399-0012.2003.00054.x

10.1111/j.1600-6143.2004.00693.x

10.1182/blood.V99.7.2592

Haque T, 1998, J. Immunol., 160, 6204, 10.4049/jimmunol.160.12.6204

10.1182/blood-2002-01-0039

10.1073/pnas.96.18.10391

10.1097/01.TP.0000058745.02123.6F

10.1097/00007890-200011270-00019

10.1016/S0140-6736(02)09672-1

10.4049/jimmunol.168.2.909

10.1046/j.1365-2141.2002.03683.x

10.1097/00007890-199705150-00002

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 56 Số 1

29-44

Thông tin tác giả